This report is a valuable tool for anyone assessing the healthcare-acquired infection market and attempting to devise a strategy to successfully compete in this market. It provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.

1. Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental
Products
Published:September 2011
No.of Pages:224
Price:US $ 4850
Report Summary
* The global market for healthcare-acquired infection (HAI) treatments were
$16 billion in year 2010. This market is estimated to be around $19 billion in
the year 2011 and is forecasted to cross $30 billion by 2016 at a CAGR of
9.5% for five year period.
* Markets for infection control devices and products were $8.3 billion in the
year 2010 and are expected to reach $10.3 billion by 2011. This market is
forecasted to cross $18.3 billion by 2016 at a CAGR of 12%.
* The market for pharmaceutical treatments is expected to be around $4.5
billion. This market is expected to increase at a 5.8% compound annual
growth rate (CAGR) to reach $6 billion by 2016.
INTRODUCTION
REASONS FOR DOING THE STUDY
The objective of this study is to provide an in-depth analysis and forecast of
the selected areas of the global healthcare-acquired infection market. HAI is
sometimes used to mean hospital-acquired infections, but for purposes of
this report, HAI includes hospitals, nursing homes, outpatient surgery
centers, and dialysis centers. Another term for healthcare-acquired
infections is nosocomial infections.
The focus of this report is on devices, pharmaceuticals, and therapies
currently used or under development for treatment of viral, bacterial, or
fungal infections.
The global market for HAI products is estimated at between $10 billion and
$15 billion in 2010, depending on the products included in the study, with
high single-digit growth through 2016. Although the U.S. holds between
45% and 50% of the market, the fastest-growing regions for HAI treatments
are the Asia-Pacific, which includes China, and Brazil.

2. STUDY GOALS AND OBJECTIVES
Healthcare-acquired infections are viral, bacterial, or fungal infections that
patients acquire after they are admitted to a healthcare facility. Patients can
acquire these infections from routine care; surgery; or as a complication
from the use of medical devices such as ventilators, catheters, and
intravenous lines.
The Centers for Disease Control (CDC) estimates that 2 million HAIs occur
annually in the U.S. This leads to 100,000 deaths and costs an additional
$36 billion to $45 billion in direct medical costs annually.
The report Healthcare-Acquired Infection: Devices, Pharmaceuticals, and
Environmental Products is designed to investigate the global HAI market by
treatment area and by treatment type, with supporting tables and figures to
illustrate projected growth. The report will include the U.S., Europe, Japan,
and other countries such as China.
This report offers forecasts of the markets for devices, pharmaceuticals, and
therapies by treatment segment and treatment type from 2011 through
2016, including supporting analyses for projections.
This report is a valuable tool for anyone assessing the healthcare-acquired
infection market and attempting to devise a strategy to successfully compete
in this market. It provides background on the structure of the HAI market
and the chief challenges and opportunities it faces. It offers the information
needed to understand the current market and to address the emerging one.
This is an invaluable tool for business planners; acquisition specialists;
licensing strategists; product managers; market research analysts; investing
consultants; and others interested in the HAI market, its products, its
participants, and its future.
Browse All Pharmaceuticals Market Research Reports
METHODOLOGIES AND INFORMATION SOURCES
Information for this report was obtained from various primary and secondary
research sources, including industry analysts, annual reports, Securities and
Exchange Commission (SEC) reports, the World Health Organization (WHO),
the National Institutes of Health (NIH), American Hospital Association (AHA),
Infectious Disease Society of America (IDSA), American Society of Heating,
Refrigerating and Air Conditioning Engineers (ASHRAE), National Institute of

3. Allergy and Infectious Diseases (NIAID), the National Hospital Discharge
Survey (NHDS), government agencies outside the U.S, and journal articles.
Secondary sources include literature searches, product literature, and press
releases.
When precise information was unavailable, a consensus is made using
reasonable assumptions and estimates based on historical data.
Table Of Contents
CHAPTER ONE: INTRODUCTION
REASONS FOR DOING THE STUDY
STUDY GOALS AND OBJECTIVES
METHODOLOGIES AND INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC REPORTS
BCC ONLINE SERVICES
DISCLAIMER
CHAPTER TWO: SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR HAI TREATMENTS, THROUGH 2016
($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR HAI TREATMENTS BY
GEOGRAPHICAL AREA, 2010 AND 2016 (%)
CHAPTER THREE: OVERVIEW
TABLE 1 GLOBAL PREVALENCE OF HEALTHCARE-ACQUIRED INFECTIONS
(PER 100 PATIENTS)
IMPORTANCE OF HAND WASHING
MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS
TABLE 2 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED INFECTIONS
GRAM-POSITIVE BACTERIA
S. AUREUS
Transmission Routes
MRSA
Rate of Infection
Transmission Routes
TYPES OF PNEUMONIA
Pseudomonas Aeruginosa
Hospital-Acquired Pneumonia
Klebsiella Pneumonia
CLOSTRIDIUM DIFFICILE
MYCOBACTERIUM TUBERCULOSIS

4. Scope of Infection
E. COLI
UTI Treatment Options
GASTROENTERITIS-CAUSING BACTERIA
Treatment Options
VANCOMYCIN-RESISTANT ENTEROCOCCI
Types of VRE
LEGIONELLA BACTERIA
Treatment Options
GRAM-NEGATIVE BACTERIA
PSEUDOMONAS AERUGINOSA
ACINETOBACTER BAUMANNII
STENOTROPHOMONAS MALTOPHILIA
VIRAL INFECTIONS
VIRAL INFECTION RESEARCH
HEPATITIS B AND C
Scope of Infection
Treatment
HIV
Treatment
NOROVIRUS
INFLUENZA VIRUS
Influenzavirus A, B, C
Transmission
Symptoms
Treatment
RESPIRATORY SYNCYTIAL VIRUS
Treatment
FUNGAL INFECTIONS
ASPERGILLUS INFECTIONS
Treatment
YEAST INFECTIONS
Candida Infections
PREVENTING HAI
DETERMINING THE MODE OF TRANSMISSION
CDC RECOMMENDATIONS FOR PREVENTION
TABLE 3 CDC MEASURES FOR PREVENTION OF HEALTHCAREACQUIRED
INFECTIONS, 2007
ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION CONTROL
INDIVIDUALS
TABLE 4 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM
MEMBERS
COMPONENTS OF A HAI SURVEILLANCE SYSTEM

5. TABLE 5 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE
INFECTION-CONTROL SURVEILLANCE SYSTEM
SUITABLE SURVEYS IN DEVELOPING COUNTRIES
HEALTHCARE INFECTION POINTS OF GENERATION
HOSPITALS
SURGICAL PROCEDURES
AMBULATORY SURGERY CENTERS IN THE U.S.
Number of Procedures in ASCs
Infection Control in ASCs
DIALYSIS CENTERS
U.S. Dialysis Centers
Transmission of VRE
Hepatitis Transmission in U.S. Dialysis Centers
Hepatitis Transmission in Dialysis Centers Outside the U.S.
ASSISTED LIVING AND LONG-TERM CARE FACILITIES
TREATMENTS
PROACTIVE MEASURES
Environmental Controls
Device Design
REACTIVE MEASURES
CHANGES IN THE INDUSTRY
TABLE 6 SELECTED MERGERS AND/OR ACQUISITIONS, 2005-2011 ($
MILLIONS)
CHAPTER FOUR: GLOBAL HEALTHCARE-ACQUIRED INFECTION
MARKET
U.S. MARKET
U.S. HEALTHCARE SPENDING
SCOPE OF HEALTHCARE-ACQUIRED INFECTIONS IN U.S.
Ventilator-Associated Pneumonia
RATE OF INFECTION
Intensive Care Units
Surgical Site Infections
Fungal Infections
COSTS
U.S. PREVENTION ACTION PLAN
TABLE 7 HHS ACTION PLAN FOR HAI PREVENTION (% REDUCTION)
EUROPEAN MARKET
SCOPE
HELICS
RATE OF INFECTION AND COSTS
JAPANESE MARKET
SCOPE

6. RATE OF INFECTION
CHINESE MARKET
SCOPE
RATE OF INFECTION
REST OF THE WORLD MARKET
SCOPE
RATE OF INFECTION
OPPORTUNITIES AND CHALLENGES FOR HAI INDUSTRY
MEDICAL DEVICE OPPORTUNITIES AND CHALLENGES
Challenges
ENVIRONMENTAL AND STRUCTURAL OPPORTUNITIES AND CHALLENGES
Challenges
NEW TREATMENTS
PHARMACEUTICAL MARKET OPPORTUNITIES AND CHALLENGES
TABLE 8 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS,
2005-2020
Pipeline Limitations
Global Recession
Regulatory Restrictions
Generic Competition
IMPACT OF DEMOGRAPHIC CHANGES
DEMOGRAPHIC CHANGES IN THE U.S.
DEMOGRAPHIC CHANGES OUTSIDE THE U.S.
CHAPTER FIVE: HAI PHARMACEUTICAL MARKET
GLOBAL MARKETS
ROLE OF EMERGING NATIONS
PHARMACEUTICALS USED FOR HEALTHCARE-ACQUIRED INFECTIONS
TABLE 9 GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH
2016 ($ MILLIONS)
GLOBAL GROWTH RATES FOR PHARMACEUTICALS
TABLE 10 ESTIMATED GROWTH OF PHARMACEUTICAL HEALTHCARE
SPENDING BY REGION, THROUGH 2016 (%)
VIRAL HAI PHARMACEUTICALS
TABLE 11 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION,
AND MANUFACTURER, 2010
FIGURE 1 ESTIMATED GLOBAL MARKET SHARE FOR PRESCRIPTION
PHARMACEUTICALS TO TREAT VIRAL HAI BY COMPANY, 2010 (%)
FIGURE 2 GLOBAL MARKET FOR VIRAL BY DISEASE TYPE(%)
VIRAL PHARMACEUTICAL MARKET BY CONDITION
TABLE 12 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAI
BY CONDITION, THROUGH 2016 ($ MILLIONS)
BACTERIAL HAI PHARMACEUTICALS

7. TABLE 13 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME,
INDICATION, AND MANUFACTURER, 2010
DRUG CLASSES
Aminoglycosides
B-Lactam Antibiotics
Cephalosporins
Glycopeptides
Lincosamides
Lipopeptides
Carbapenems
Penicillins
Polypeptides
Macrolides
Quinolones
Tetracyclines
Tuberculosis
Sulfonamides
Other Formulations
FIGURE 3 GLOBAL MARKET SHARE FOR PRESCRIPTION PHARMACEUTICALS
TO TREAT BACTERIAL HAI BY COMPANY, 2010 (%)
TABLE 14 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL
HAI, THROUGH 2016 ($ MILLIONS)
TABLE 15 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL
HAI BY CONDITION, THROUGH 2016 ($ MILLIONS)
FUNGAL HAI PHARMACEUTICALS
TABLE 16 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL
INFECTIONS BY NAME, TYPE, AND MANUFACTURER, 2010
TABLE 17 GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI,
THROUGH 2016 ($ MILLIONS)
FIGURE 4 MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI BY
COMPANY, 2010 (%)
GLOBAL OPPORTUNITIES
CHAPTER SIX: HAI ENVIRONMENTAL TREATMENT MARKET
GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET
TABLE 18 GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO
MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($
MILLIONS)
PLANNING FOR CONSTRUCTION OR RENOVATION: U.S.
Plans Involving Infection Control
AIR TREATMENT
ROOM FILTRATION SYSTEMS
ROOM PRESSURIZATION

8. HYDROGEN PEROXIDE VAPOR
Dedicated Airborne Isolation Rooms
WATER TREATMENT
DESIGN OF SINKS AND OTHER WATER FACILITIES
CLEANING PHYSICAL SURFACES
DISINFECTION
Advantages and Disadvantages of Disinfectants
TABLE 19 ADVANTAGES AND DISADVANTAGES OF COMMONLY USED
DISINFECTANTS
PHENOLICS
OXIDIZING AGENTS
HALOGENS
ALDEHYDES
QUATERNARY AMINES
ALCOHOLS
TABLE 20 GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TO
MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($
MILLIONS)
FIGURE 5 GLOBAL MARKET FOR DISINFECTANT PRODUCTS BY TYPE, 2010
(%)
PATIENT SKIN PREPARATION DISINFECTANTS
IODINE
POVIDONE-IODINE SOLUTIONS
CHLORHEXIDINE GLUCONATE
TABLE 21 GLOBAL MARKET FOR PATIENT PREPARATION DISINFECTANTS,
THROUGH 2016 ($ MILLIONS)
STERILIZATION SYSTEMS FOR INFECTION CONTROL
TABLE 22 GLOBAL MARKET FOR STERILIZATION DESIGNED TO MINIMIZE
HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($ MILLIONS)
CHEMICAL STERILIZATION
ETO Sterilization
Major Players in Chemical Sterilization
OTHER CHEMICAL STERILIZATION
Peracetic Acid
Hydrogen Peroxide
Chlorine Dioxide
Ozone
STEAM STERILIZATION
TABLE 23 SELECTED PLASTIC MATERIALS THAT RESPOND WELL TO STEAM
STERILIZATION
Autoclaving
Major Players in Heat Sterilization

9. CHAPTER SEVEN: HAI MEDICAL DEVICES: CATHETERS, PATIENT
VENTILATION SYSTEMS, AND IN-LINE STERILIZATION FILTERS
SELECTED GLOBAL MEDICAL HAI DEVICE MARKET
TABLE 24 GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZE
HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2016 ($ MILLIONS)
CATHETERS
USE OF COATINGS
CATHETER COATINGS
TABLE 25 SELECTED CATHETER PRODUCTS WITH ANTIBIOTIC PROPERTIES
Silver Coating
SURFACE-MODIFIED CATHETER
TABLE 26 GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL
PROPERTIES, THROUGH 2016 ($ MILLIONS)
FIGURE 6 HAI CATHETER MARKET SHARES BY URINARY, CVC, PICC, AND
OTHER SEGMENTS, 2011 AND 2016 (%)
URINARY TRACT CATHETERS
CENTRAL VENOUS CATHETERS
Dialysis Catheters
Catheter-Related Bloodstream Infections
TABLE 27 POTENTIAL SOURCES OF CRBSI
PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS
MARKET OPPORTUNITIES FOR CATHETER MANUFACTURERS
CATHETER GROWTH IN REGIONAL MARKETS
TABLE 28 GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2016 ($
MILLIONS)
FIGURE 7 GLOBAL HAI CATHETER MARKET BY REGION, 2011 AND 2016 (%)
PATIENT VENTILATION DEVICES
TABLE 29 GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS,
THROUGH 2016 ($ MILLIONS)
TYPES OF VENTILATION DEVICES
Non-Invasive Ventilators
TABLE 30 GLOBAL MARKET FOR NON-INVASIVE VENTILATIONS SYSTEMS
FOR USE WITH PATIENTS WHO HAVE HAIS, THROUGH 2016 ($ MILLIONS)
ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS
Coated Endotracheal Tubes
Tapered Endotracheal Tubes
TABLE 31 GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNED
TO MINIMIZE VAP, THROUGH 2016 ($ MILLIONS)
IN-LINE STERILE IV FILTRATION
TABLE 32 GLOBAL STERILE IV FILTER MARKET, THROUGH 2016 ($
MILLIONS)

10. CHAPTER EIGHT: REGULATIONS AND PATENTS
U.S. INFECTION CONTROL PROGRAMS
INFECTION CONTROL MEASURES AND PROTOCOLS
U.S. REGULATIONS
HOSPITAL INFECTIONS DISCLOSURE ACT
CURRENT AND PENDING REQUIREMENTS
Affordable Care Act and Implications for the Pharmaceutical Industry
Biosimilars
CMS Reimbursement for HAIs
EUROPEAN REGULATIONS
IMPLICATIONS FOR PHARMACEUTICAL MANUFACTURERS
JAPANESE REGULATIONS
CHINESE REGULATIONS
PATENTS
PATENTS BY MANUFACTURER
TABLE 33 PATENTS BY MANUFACTURER, 2005-2011
PATENTS BY DATE OF ISSUE
TABLE 34 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, 2005-2011
PATENTS BY MANUFACTURER
TABLE 35 PATENTS BY MANUFACTURER
PATENTS FOR DELIVERY OF PHARMACEUTICALS
TABLE 36 PATENT BY INDICATION: PHARMACEUTICAL DELIVERY, 2005-
2011
BACTERIAL PHARMACEUTICAL PATENTS
TABLE 37 PATENTS BY INDICATION: BACTERIAL PHARMACEUTICAL, 2005-
2011
FUNGAL PHARMACEUTICAL PATENTS
TABLE 38 PATENT BY INDICATION: FUNGAL PHARMACEUTICAL, 2010
VIRAL PHARMACEUTICAL PATENTS
TABLE 39 PATENTS BY INDICATION: VIRAL PHARMACEUTICAL, 2005-2011
ENVIRONMENTAL CONTROLS
TABLE 40 PATENT BY INDICATION: AIR FILTRATION, 2005-2011
TABLE 41 PATENTS BY INDICATION: WATER TREATMENT, 2005-2011
PATENTS FOR SURFACE DISINFECTANTS
TABLE 42 PATENTS BY INDICATION: DISINFECTANT SURFACES, 2005-2011
TABLE 43 PATENT BY INDICATION: SOLID WASTE TREATMENT, 2005-2011
PATENTS FOR DIAGNOSTIC PROCESSES
TABLE 44 PATENTS BY INDICATION: DIAGNOSTIC, 2006-2011
MEDICAL DEVICES
TABLE 45 PATENTS BY INDICATION: CATHETER, 2008-2011
TABLE 46 PATENTS BY INDICATION: ANTIMICROBIAL COATINGS, 2005-
2011

11. CHAPTER NINE: CURRENT RESEARCH AND EMERGING THERAPIES
EMERGING RESEARCH
RAPID TESTING
ANTISEPTIC WASHES
PHARMACEUTICALS
MERCK
Boceprivir
VERTEX
Teleprivir
TIBOTEC
CEREXA
Ceftaroline
NXL104
BASILEA PHARMACEUTICALS
Ceftobiprole
Delafloxacin
JOHNSON & JOHNSON
Doribax
CUBIST PHARMACEUTICALS
CSA-201
CXA183,315
TOYAMA CHEMICAL
T-705
T-3912
T-2307
GLAXOSMITHKLINE
OPTIMER PHARMACEUTICALS
Fidaxomicin
AURICX
BPH-652
PFIZER
THE MEDICINES COMPANY
Oritavancin
STERILIZATION AND DISINFECTION
SHARKLET TECHNOLOGIES
HEALTHCARE FACILITY DESIGN
MEDICAL DEVICE DESIGN
ONDINE BIOMEDICAL
CERAGENIX PHARMACEUTICALS, INC.
RENAL SEPSIS MICROFILTER
CHAPTER TEN: COMPANY PROFILES

12. PHARMACEUTICALS
ABBOTT LABORATORIES
Business Overview
Financials
Products
ASTELLAS PHARMA, INC.
Business Overview
Financial Information
Products
ASTRA TECH
ASTRAZENECA, PLC
Business Overview
Financials
Products
BACTIGUARD, AB
Business Overview
Financials
Products
BASILEA PHARMACEUTICA, LTD.
Business Overview
Financials
Products
BAYER, AG (MILES-BAYER)
Business Overview
Financials
Products
BOEHRINGER INGELHEIM, GMBH
Business Overview
Financials
Products
BRISTOL-MYERS SQUIBB
Business Overview
Financials
Products
CEREXA, INC. (FOREST LABORATORIES)
Business Overview
Financials
Products
CUBIST PHARMACEUTICALS
Business Overview
Financials
Products
ELAN CORPORATION

13. Business Overview
Financials
Products
FOREST LABORATORIES
Business Overview
Financials
Products
ELI LILLY AND COMPANY
Business Overview
Financials
Products
GILEAD SCIENCES
Business Overview
Financials
Products
GLAXOSMITHKLINE
Business Overview
Financials
Products
JOHNSON & JOHNSON
Business Overview
Financial Information
Products
MEDIMMUNE PHARMACEUTICALS
Business Overview
Financials
Products
MERCK
Business Overview
Financials
Products
NABI BIOPHARMACEUTICALS
Business Overview
Financials
Products
PFIZER
Business Overview
Financials
Products
ROCHE PHARMACEUTICALS
Business Overview
Financials
Products

14. SANOFI AVENTIS
Business Overview
Financials
Products
SCHERING-PLOUGH
THE MEDICINES COMPANY
Business Overview
Financials
Products
THERAVANCE
Business Overview
Financials
Products
TOYAMA CHEMICAL CO, LTD.
Business Overview
Financials
Products
VERTEX PHARMACEUTICALS, INC.
Business Overview
Financials
Products
VIROPHARMA, INC.
Business Overview
Financials
Products
ENVIRONMENTAL PRODUCTS
3M HEALTHCARE, MEDICAL DIVISION
Business Overview
Financials
Products
ADVANCED STERILIZATION PRODUCTS
Business Overview
Financials
Products
ANDERSEN PRODUCTS, INC.
Business Overview
Financials
Products
BAXTER INTERNATIONAL
Business Overview
Financials
Products
DIVERSEY, INC

15. Business Overview
Financials
Products
ECOLAB
Business Overview
Financials
Products
GETINGE USA, INC.
Business Overview
Financials
Products
PRIMUS STERILIZER CO., INC.
Business Overview
Financials
Products
RUHOF CORP.
Business Overview
Financials
Products
STERIGENICS
Business Overview
Financials
Products
STERIS CORP.
Business Overview
Financials
Products
TUTTANAUER USA CO., LTD.
Business Overview
Financials
Products
ULTRAVIOLET DEVICES, INC.
Business Overview
Financials
Products
XENEX HEALTHCARE SERVICES
Business Overview
Financials
Products
INFECTION CONTROL DEVICES
B. BRAUN MELSUNGEN, AG
Business Overview
Financials

16. Products
BECTON DICKINSON
Business Overview
Financials
Products
BIOMÉRIEUX, INC.
Business Overview
Financials
Products
CANTEL MEDICAL CORP.
Business Overview
Financials
Products
CAREFUSION CORP.
Business Overview
Financials
Products
CEPHEID
Business Overview
Financials
Products
CLOROX CO.
Business Overview
Financials
Products
COLOPLAST GROUP
Business Overview
Financials
Products
CONVATEC
Business Overview
Financial
Products
COOK MEDICAL
Business Overview
Financials
Products
COVIDIEN, PLC
Business Overview
Financials
Products
CR BARD
Business Overview

17. Financials
Products
DRAGER MEDICAL, LTD., U.K.
Business Overview
Financials
Products
HOLLISTER, INC.
Business Overview
Financials
Products
KIMBERLY-CLARK HEALTHCARE
Business Overview
Financials
Products
ODINE BIOMEDICAL, INC.
Business Overview
Financials
Products
TELEFLEX MEDICAL
Business Overview
Financials
Products
WELCH ALLYN, INC.
Business Overview
Financials
Products
About Us:
ReportsnReports is an online library of over 100,000+ market research
reports and in-depth market research studies & analysis of over 5000 micro
markets. We provide 24/7 online and offline support to our customers. Get
in touch with us for your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page:
http://www.facebook.com/pages/ReportsnReports/191441427571689

18. Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog